Navigation Links
Tute Genomics and DNAnexus Team Up to Provide Integrated Sample-in, Report-out Genome Analysis Pipeline
Date:3/17/2015

PROVO, Utah and MOUNTAIN VIEW, Calif., March 17, 2015 /PRNewswire/ -- DNAnexus, a pioneer in cloud-based genome informatics and data management, and Tute Genomics, a leading genome annotation and interpretation platform, today announced an integrated solution for genomic data management. Customers will be able to access the Tute platform and DNAnexus pipelines form either company's cloud environment.

DNAnexus provides an enterprise-level solution that combines cloud computing with advanced bioinformatics to power genomic analysis tools. Tute Genomics specializes in genome analysis, creating meaningful reports of an individual's full genomic profile that researchers/clinicians can interpret, or performing association analysis to gain critical insights into the molecular basis of diseases. The collaboration between the two companies allows Tute Genomics to provide its customers with an end-to-end solution, where a clinical researcher can take raw sequence data through genome interpretation in a single step. 

"The DNAnexus platform is becoming the go-to solution for data interpretation tool providers who are seeking a secure, compliant and scalable platform on which they can deploy and expand their product portfolios," said Richard Daly, CEO of DNAnexus. "We are proud of the collaboration with Tute Genomics, which has enabled our mutual customers to move seamlessly between the two environments in a powerful new end-to-end analytical solution for genomic biomarker discovery and interpretation."

Reid Robison, CEO of Tute Genomics, commented on the DNAnexus partnership: "We have a passion to enable precision medicine in fast and affordable manner through genome sequencing. The integration with DNAnexus brings expertise from both companies together to offer an integrated, end-to-end solution for both research and clinical users, accelerating the pace of scientific discoveries and enabling the implementation of personalized medicine." 

Clinical researchers can now easily perform best practice data analysis and bring the world's scientific literature together without the hassle of connecting multiple systems, transferring large files or deploying costly local solutions. Web-based tools allow labs or their sequencing providers to upload raw sequence data files directly onto DNAnexus, where these data will be automatically processed through proprietary pipelines developed by Tute to generate "VCF" data files that can be analyzed using Tute's genome interpretation solutions.

"Tute and DNAnexus share a common vision to make genomics more accessible to healthcare providers, scientific researchers and even consumers, in order to advance individualized, genome-guided medicine," said Dr. Kai Wang, President and Co-Founder of Tute Genomics. "Through our collaboration with DNAnexus, we can now offer Tute customers upstream primary analyses and downstream interpretations in a seamless fashion, which will ultimately help make medical intervention and care decisions easily and rapidly." 

Juneau Biosciences, which focuses on the diagnosis and treatment of common women's health conditions, is an early adopter of this new integrated pipeline.  Juneau uses the Tute platform for endometriosis biomarker discovery.  Prior to an integrated pipeline with DNAnexus, Juneau performed variant calling and alignment in-house, and then manually transferred variant files to Tute for annotation and analysis.  As the project scaled, their local pipeline became computationally taxing and unsustainable.  The cloud offers near-infinite scalability, and the new integrated pipeline allows Juneau's data to flow seamlessly from next-generation sequencer, through variant calling and alignment in the DNAnexus environment, to discovery and interpretation in the Tute platform.

Dr. Ken Ward, Founder and CEO of Juneau Biosciences shared that: "The integration of Tute with DNAnexus greatly expands Juneau's bioinformatics capability and provides a scalable solution as we continue to grow.  This cloud-based solution is saving Juneau hundreds of thousands of dollars that we would have to spend on our own in-house hardware and programming."

As part of this collaboration, DNAnexus has created an export tool, available to customers via the DNAnexus App Library, which enables customers to securely transfer genome variants data into the Tute Genomics solution for downstream analysis, including annotation, interpretation and clinical reporting. Similarly, Tute has created a data uploader, where users of the Tute platform can directly upload FASTQ files from next-generation sequencers, generate variant calls, annotate the genetic variant data, perform association analysis and interactively draft clinical reports on the Tute platform.

About DNAnexus
DNAnexus accelerates the development and delivery of genomic medicine with a global network for sharing and managing genomic data and tools. DNAnexus provides a technology infrastructure and toolset that is optimized for addressing the challenges of security, scalability and collaboration, for organizations that are pursuing genomic-based approaches to health, in the clinic and in the research lab. The DNAnexus team is made up of experts in computational biology and cloud computing who are working with organizations to tackle some of the most exciting opportunities in human health, making it easier—and in many cases feasible—to work with genomic data. With DNAnexus, organizations can stay a step ahead in leveraging genomics to achieve their goals. The future of human health is in genomics. DNAnexus brings it all together. For more information please visit: https://dnanexus.com.

About Tute Genomics
Tute Genomics is a Utah-based company that is powering the world's genomic knowledge with a cloud-based solution for precision, genome-guided medicine.  Tute provides a clinical genome interpretation platform that helps researchers identify disease genes and biomarkers, and assists clinicians/labs with genetic diagnosis and personalized therapeutics. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation and interpretation technology with over 1,000 scientific citations. The genome revolution is here, and Tute envisions a future where genome sequencing is part of routine clinical care. Tute integrates genomic data into medical records to give doctors and patients alike access to genetic information at their fingertips where it is most useful and actionable. Genomics is changing healthcare as we know it, and Tute is helping to shape the future of medicine: unlocking the genome, personalizing treatment and powering discovery. To learn more please visit www.tutegenomics.com and follow us on twitter @TuteGenomics.

Media Contacts:

For DNAnexus:

Tim Smith
Element Public Relations
415-350-3019
Email

For Tute Genomics:

Mary Brown
858-779-4363
Email


'/>"/>
SOURCE Tute Genomics
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. CrystalGenomics Partners with Daewoong Pharmaceutical for Acelex Commercialization in Korea
2. Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics
3. Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial
4. BioNanos Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation
5. BioNano Genomics Announces One Human : One Chip : One Day
6. Cypher Genomics Forms Scientific Advisory Board to Advance Genome Interpretation and Biomarker Discovery Services
7. Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer
8. Axio Launches Statistical Genetics & Genomics Services
9. Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery
10. Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics Targeted Next Generation Sequencing Testing Platform
11. Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2019)... ... July 10, 2019 , ... ... clinical study from Ohio State University Wexner Medical Center for PrimaVie®, its ... acid, and micro minerals. Natreon is committed to continued scientific investment and ...
(Date:7/10/2019)... , ... July 10, 2019 , ... DidCBDWork.com ... world for the past 18 months, does CBD actually work? It seems like depending ... snake oil. , DidCBDWork.com instead aims to get testimonials of real CBD users, ...
(Date:7/9/2019)... ... July 10, 2019 , ... FDA Data Integrity, ... Cerulean Associates LLC and FDAnews**, Oct. 21-22, 2019, Doubletree by Hilton Hotel Bethesda ... Register by Sept. 23 and Save $200 , FDA gives simple instructions to ...
Breaking Medicine Technology:
(Date:7/10/2019)... ... July 10, 2019 , ... Foggiare --the first and only ... and effective beauty and wellness technology. Developed by Sauna Italia , an Italian ... already a proven success in over 180 locations in Europe and Asia. Slim-Up is ...
(Date:7/10/2019)... ... July 10, 2019 , ... Given that ... Grove Fertility (SGF) remains committed to its core mission of fertility education ... of July, the practice will host six in-person seminars and three virtual webinars ...
(Date:7/9/2019)... ... ... Excellence is excited to offer laser vaginal rejuvenation. Laser vaginal rejuvenation gives women a less ... painful sex , vaginal dryness and burning , vaginal ... vaginal pH imbalances , recurrent vaginal infections , vaginal ...
(Date:7/9/2019)... ... July 09, 2019 , ... Complete Nutrition , a ... transition from a brick-and-mortar only business toward an e-commerce company. With 15 years of ... meet the growing demands of digital consumers. , As part of the transition, ...
(Date:7/9/2019)... ... July 09, 2019 , ... Smile Brands Inc., ... to more than 400 affiliated offices across 17 states, is pleased to announce ... Brands will provide full-service administrative support to the practice, including; purchasing, payroll, accounting, ...
Breaking Medicine News(10 mins):